Eli Lilly

News

Lilly’s antibody for COVID-19 protection starts nursing home...

While the world waits an effective coronavirus vaccine, Eli Lilly has started late-stage human testing an antibody drug as an alternative way to prevent viral transmission in h

News

Study puts Jardiance in hot pursuit of AZ’s Farxiga in heart...

The FDA’s approval of AstraZeneca’s SGLT2 inhibitor Farxiga in heart failure was a first for the class, but Boehringer Ingelheim and Eli Lilly are closing the gap with a positi

News

Doctor Checking Skin Of Patient With Magnifying Glass

Lilly’s mirikizumab tops Novartis’ blockbuster Cosentyx in p...

Eli Lilly is a latecomer in the new generation of biologic therapies for psoriasis with its mirikizumab candidate, but a win in a head-to-head trial against Novartis’ big-selli

News

J&J's Tremfya to join crowded psoriatic arthritis market aft...

The FDA has approved a label extension for Johnson & Johnson’s Tremfya (guselkumab) in psoriatic arthritis, the first drug from the IL-23 class to gain a foothold in this indication.

News

Roche signs $1.7bn deal with Blueprint around cancer drug pr...

Roche has signed a global collaboration worth up to $1.7 billion with cancer drugs firm Blueprint Medicines based around pralsetinib, a drug that targets tumours with RET mutations.

News

FDA grants fast review of AZ's Brilinta to prevent recurring...

The FDA has granted a fast review of AstraZeneca’s cardiovascular diseases drug Brilinta (ticagrelor) in the new indication that aims to reduce the chances of patients having recurring stro

Lilly’s antibody for COVID-19 protection starts nursing home...

Study puts Jardiance in hot pursuit of AZ’s Farxiga in heart...

Lilly’s mirikizumab tops Novartis’ blockbuster Cosentyx in p...

J&J's Tremfya to join crowded psoriatic arthritis market aft...

Roche signs $1.7bn deal with Blueprint around cancer drug pr...

FDA grants fast review of AZ's Brilinta to prevent recurring...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Eli Lilly

Editor's Picks